Korean National Health Insurance Covers Novartis Galvus In Second-Line Type 2 Diabetes
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Novartis Korea's DPP-4 inhibitor type 2 diabetes treatment Galvus (vildagliptin) will be covered by South Korea's National Health Insurance Policy beginning Feb. 1 for second-line treatment
You may also be interested in...
Roche Is Latest MNC To Partner A Primary Care Product In Korea
Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.
Emerging Market Outlook: PharmAsia News Earnings Call Roundup
In a new feature, PharmAsia News takes a look at the earnings calls for some of the major pharma companies and what they are saying about Asia Pacific and emerging markets
Emerging Market Outlook: PharmAsia News Earnings Call Roundup
In a new feature, PharmAsia News takes a look at the earnings calls for some of the major pharma companies and what they are saying about Asia Pacific and emerging markets